Bonus Material-01_Restrepo_Pneumonias_CHEST_BR_2025

Pdf Summary

This comprehensive lecture by Dr. Marcos I. Restrepo focuses on the epidemiology, diagnosis, treatment, and prevention of pneumonia, specifically community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP).<br /><br />For CAP, recent trends highlight the complexity of pathogen-host interactions, including common pathogens like Streptococcus pneumoniae, influenza, and SARS-CoV-2. Risk factors include advanced age, comorbidities, and immunosuppression. Diagnosis increasingly incorporates thoracic ultrasound, which shows high sensitivity and specificity compared to chest radiography. Severity assessment tools such as PSI, CURB-65, and ATS/IDSA criteria help guide management decisions. Treatment emphasizes appropriate antibiotic selection with an emphasis on de-escalation and short course therapy — as few as 3 to 5 days in stable patients—guided by clinical stability and biomarkers such as CRP and procalcitonin. Newer guidelines also address viral-bacterial co-infections, recommending empiric antibiotics in patients with comorbidities or severe disease and cautioning against routine corticosteroids except possibly in severe non-influenza CAP with elevated inflammation markers. Prevention includes vaccination (influenza, pneumococcal) and healthy habits.<br /><br />Regarding HAP and VAP, these nosocomial infections occur after 48 hours in hospital or ventilation, respectively, often involve multidrug-resistant (MDR) Gram-negative bacteria like Pseudomonas aeruginosa and Acinetobacter baumannii, and have substantial mortality and healthcare costs. Diagnosis includes microbiological sampling (endotracheal aspirates, BAL) combined with clinical assessment and limited use of biomarkers. Treatment is guided by risk assessment for MDR pathogens, institution-specific antibiograms, and new antibiotics such as sulbactam-durlobactam targeting resistant Acinetobacter. De-escalation strategies and duration of therapy (typically 7 days) are key to stewardship. Prevention focuses on evidence-based interventions including oral care, minimizing ventilation duration, and suctioning protocols to reduce VAP incidence.<br /><br />In sum, pneumonia management demands integration of updated epidemiology, diagnostic modalities, antibiotic stewardship, and preventive measures tailored for community and healthcare settings to improve patient outcomes and combat resistance challenges.

Meta Tag

Concept Community-Acquired Pneumonia

Concept Nosocomial Pneumonia

Concept Ventilator-Associated Pneumonia

Concept Empiric Antibiotic Therapy

Concept Targeted Antibiotic Therapy

Keywords

pneumonia

community-acquired pneumonia

hospital-acquired pneumonia

ventilator-associated pneumonia

diagnosis

antibiotic stewardship

multidrug-resistant bacteria

thoracic ultrasound

vaccination

procalcitonin

Community-Acquired Pneumonia

Nosocomial Pneumonia

Ventilator-Associated Pneumonia

Empiric Antibiotic Therapy

Targeted Antibiotic Therapy